MX2024009485A - Vacunas terapeuticas anti-alfa-sinucleina. - Google Patents

Vacunas terapeuticas anti-alfa-sinucleina.

Info

Publication number
MX2024009485A
MX2024009485A MX2024009485A MX2024009485A MX2024009485A MX 2024009485 A MX2024009485 A MX 2024009485A MX 2024009485 A MX2024009485 A MX 2024009485A MX 2024009485 A MX2024009485 A MX 2024009485A MX 2024009485 A MX2024009485 A MX 2024009485A
Authority
MX
Mexico
Prior art keywords
present
defined above
peptide antigen
synuclein
alpha
Prior art date
Application number
MX2024009485A
Other languages
English (en)
Spanish (es)
Inventor
Andrea Pfeifer
Maxime Ayer
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of MX2024009485A publication Critical patent/MX2024009485A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2024009485A 2022-02-09 2023-02-09 Vacunas terapeuticas anti-alfa-sinucleina. MX2024009485A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22156007 2022-02-09
EP22156006 2022-02-09
PCT/EP2023/053259 WO2023152260A1 (en) 2022-02-09 2023-02-09 Anti-alpha-synuclein therapeutic vaccines

Publications (1)

Publication Number Publication Date
MX2024009485A true MX2024009485A (es) 2024-08-14

Family

ID=85175955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009485A MX2024009485A (es) 2022-02-09 2023-02-09 Vacunas terapeuticas anti-alfa-sinucleina.

Country Status (11)

Country Link
US (1) US20250152684A1 (enExample)
EP (1) EP4475878A1 (enExample)
JP (1) JP2025506472A (enExample)
KR (1) KR20240147981A (enExample)
AU (1) AU2023219059A1 (enExample)
CA (1) CA3248093A1 (enExample)
CL (1) CL2024002370A1 (enExample)
CR (1) CR20240371A (enExample)
IL (1) IL314865A (enExample)
MX (1) MX2024009485A (enExample)
WO (1) WO2023152260A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024211543A1 (en) * 2023-01-26 2025-07-17 Ac Immune Sa Liposomal construct
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
EP2659907A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
US12156912B2 (en) * 2012-05-18 2024-12-03 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
RU2734924C2 (ru) 2015-11-03 2020-10-26 Аффирис Аг Способ вакцинации против аутоантигена у пациента-человека
CN111787942B (zh) * 2017-10-25 2024-03-29 杨森制药公司 磷酸化Tau肽的组合物及其用途
AU2019253193B2 (en) * 2018-04-10 2026-02-05 Ac Immune Sa Anti-abeta therapeutic vaccines
CA3185563A1 (en) * 2020-08-04 2022-02-10 Dorian WINTER Immunogenic compounds

Also Published As

Publication number Publication date
WO2023152260A1 (en) 2023-08-17
CR20240371A (es) 2024-10-16
AU2023219059A1 (en) 2024-07-25
JP2025506472A (ja) 2025-03-11
CA3248093A1 (en) 2023-08-17
US20250152684A1 (en) 2025-05-15
CL2024002370A1 (es) 2024-12-27
KR20240147981A (ko) 2024-10-10
IL314865A (en) 2024-10-01
EP4475878A1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
CL2024002370A1 (es) Vacunas terapeuticas anti-alfa-sinucleína.
IL152625A (en) Synthetic but not amyloidogenic immunogenic peptides equivalent to amyloid b to elicit an immune response to amyloid b and amyloid deposits
CY1105597T1 (el) Ανοσοθεραπευτικες μεθοδοι χρησιμοποιωντας επιτοπους των wt-1 και gata-1
CA2489227A1 (en) Hla-a24-restricted cancer antigen peptides
DK1531791T3 (da) Forebyggelse og begrænsning af iskæmi
PE20231212A1 (es) Polipeptidos variantes proteoliticamente estables de u1-agatoxina-ta1b para el control de plagas
RU2009119597A (ru) Новые белки н5, кодирующие их молекулы нуклеиновых кислот и векторы, и их применение в медицине
AR123187A1 (es) Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer
RU2013112616A (ru) Пептид cdca1 и включающее его фармацевтическое средство
AR120891A1 (es) Proteína rsv f mutante y su uso
ATE527364T1 (de) Polypeptide erhaltend eine modifizierte menschliche serum-albumin sekretions-pre-sequenz mit erhöhtem ausscheidungsertrag
CO2021017664A2 (es) Péptidos
MX2023005770A (es) Tetrapeptido y composiciones que comprenden tetrapeptidos.
PE96899A1 (es) Genes aislados de proteinas de membranas de mamiferos; reactivos relacionados
PE20231952A1 (es) Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina
MX2023001483A (es) Compuestos inmunogenicos.
CU24746B1 (es) Apirasas humanas, solubilizadas y modificadas útiles para prevenir y tratar el daño tisular
Fujii et al. Inversion and isomerization of Asp-58 residue in human αA-crystallin from normal aged lenses and cataractous lenses
MXPA06014393A (es) Peptidos oligomericos y su uso para el tratamiento de infecciones por vih.
RU2010126154A (ru) Эпитопные пептиды stat3
NZ592340A (en) A method for making a virus vaccine compising Replikin peptides
ATE509025T1 (de) ßMIT MHC-KLASSE-I-PEPTIDEPITOPEN KOVALENT VERKN PFTES MEMBRANVERANKERTES BETA2-MIKROGLOBULINß
PH12023553212A1 (en) Improved methods of treatment using immunogenic peptides
AR069047A1 (es) Peptidos y lipopeptidos sinteticos antigenicos derivados de mycobacterium avium subsp. paratuberculosis
Murata et al. Novel biologically active peptides from the venom of Polistes rothneyi iwatai